Mitochondrial diseases are heterogeneous in clinical presentation and genotype. The incidence of known pathogenic mitochondrial DNA mutations in the general population is 1 in 500. Little is known about the implications of pregnancy for women with mitochondrial disease. We undertook a systematic review of the literature on mitochondrial disease in pregnancy. Ten case reports were identified. The most common complications were threatened preterm labour (5 women) and preeclampsia (4 women). Two women experienced magnesium sulphate toxicity. Pregnancy had a varied effect on mitochondrial disease with some women being asymptomatic; others developing mild symptoms such as exercise intolerance or muscle weakness which resolved postnatally; and others developed more serious, persistent symptoms such as symptomatic Wolff -Parkinson -White syndrome, persistent paraesthesia and focal segmental glomerulosclerosis. Women with mitochondrial disease appear to be at increased risk of complications during pregnancy and labour but further prospective cohort studies are needed.
INTRODUCTION
Mitochondria generate energy in the form of adenosine triphosphate (ATP) by oxidative phosphorylation. Mitochondrial diseases, in which this process is impaired, can present at any age with phenotypically heterogeneous manifestations that are characterized by multisystem involvement. 1 A general feature is that tissues with the highest energy requirement are predominantly affected. Typical features include: deafness, diabetes, proximal myopathy, external ophthalmoplegia, visual loss, gastrointestinal dysmotility, cardiomyopathy, cardiac conduction defects, epilepsy and in rarer cases encephalopathy and strokelike episodes. 1 Mitochondria have their own genome which is maternally inherited. 1 This small circular DNA molecule (mtDNA) encodes two rRNAs, 22 tRNAs and 13 of the 90 proteins that make up the respiratory chain; however, the remaining respiratory chain proteins, along with mitochondrial DNA maintenance proteins, are nuclear encoded. Mitochondrial diseases can therefore show a variety of inheritance patterns. Point mutations in the mtDNA molecule (such as the m.3243A . G mutation) show maternal inheritance; large-scale mtDNA re-arrangements (for example single deletions) arise sporadically, and typically are not passed on. Multiple mtDNA deletions, which arise gradually as a result of mutations of nuclear-encoded mtDNA replication and repair enzymes, show either autosomal dominant or recessive inheritance. At-risk mothers may therefore not have an obvious family history of mitochondrial disease, and similarly, the risk to their fetus depends to a large degree on the mode of inheritance of their disease.
The range of possible clinical presentations is very broad, and diagnosis may be difficult. This is as a result of the large number of mtDNA mutations that have been described to date, 2 -29 and also the range of syndromes arising as a result of a given mutation. For example, the m.3243A . G mutation may cause both the relatively mild MIDD (maternally inherited diabetes and deafness) syndrome, 16 or the far more severe MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) syndrome. 24 Important syndromes of mitochondrial disease and their associated genetic mutations are summarized in Table 1 . Unfortunately, many patients do not fall into any clearly defined syndrome, or have an as yet undescribed mutation; in these cases diagnosis depends on the recognition of typical symptoms with supporting evidence from mtDNA sequencing, histochemical investigation (e.g. ragged-red fibres seen in muscle biopsy specimens) and biochemistry (measurement of mitochondrial enzyme activities). 1 The prevalence of mitochondrial disease is difficult to estimate. The first genetic defects were identified in 1988, and it was initially thought that mitochondrial disease was relatively rare. However, the incidence of known pathogenic mtDNA mutations in the general population has recently been investigated. These studies have shown that approximately 1 in 500 individuals carry the m.3243A . G mutation, which can cause severe neurological disease, with a similar figure observed for the m.1555A . G mutation, which causes aminoglycoside-induced deafness. 30 -32 Another approach to study the incidence of mtDNA disease is to document the number of clinically affected cases within a specific geographic region. This approach is limited because there is marked clinical variability which means many patients go unrecognized and because patients may not be referred to specialist centres. However, even these studies show there is a high disease burden with at least 1 in 10,000 of the adult population suffering from mtDNA disease. 33 At present, little is known about the risk of pregnancy complications for women with mitochondrial disease or how best to counsel them preconception. The physiological changes of pregnancy, with its increased respiratory demands, lead us to hypothesize that women who already have impaired mitochondrial function may be at risk of deterioration in symptoms and obstetric complications. However, just as mitochondrial diseases are heterogeneous it is likely women may be affected variably in pregnancy.
The aim of this review is to identify studies investigating the risks of pregnancy complications in women with mitochondrial disease, to summarize what is already known and identify future research opportunities.
METHODS
We searched Medline (1950 to present) to identify citations on pregnancy and mitochondrial respiratory chain disease (search terms: pregnancy, pregnancy complications, high-risk pregnancy, mitochondrial diseases, mitochondria, DNA mitochondrial) from inception until December 2010. The reference lists of all included primary research papers were examined to identify cited papers not identified by electronic searches and, when possible, papers citing them were identified electronically.
RESULTS
Ten case reports were identified. There were no published cohort studies. These reports were of women with a variety of mitochondrial disease phenotypes and genotypes (see Table 2 ). The women experienced different modes of delivery at a range of gestations: from 25 weeks to term. The most common complications were threatened preterm labour and preeclampsia (see Table 2 ). Two women experienced magnesium sulphate toxicity when given as tocolysis 34 or for preeclampsia. 35 Some women experienced no complications in one or more of their pregnancies. 36, 37 In these cases, pregnancy had a varied effect on mitochondrial disease with some women being asymptomatic. 34, 35, 37 Other women developed mild symptoms that resolved postnatally such as exercise intolerance or muscle weakness 37, 38 and others developed more serious or persistent symptoms such as Wolff -Parkinson-White syndrome, 39 persistent paraesthesia 40 and focal segmental glomerulosclerosis. 41 In some cases, symptoms led to obstetric intervention such as induction of labour 42 or planned caesarean section. 39 
DISCUSSION
Mitochondrial disease presents a challenge for obstetricians because little is known about the relationship between mitochondrial disease and pregnancy and the evidence base is limited to the case reports discussed in this paper. Case reports are limited in their validity and reliability by their small numbers and heterogeneous clinical situations. Nevertheless, this review has raised a number of important issues for clinicians.
Women with mitochondrial disease have varied clinical presentations and genetic defects making diagnosis challenging. Women with an established diagnosis of mitochondrial disease are likely to be referred to a high-risk obstetric or obstetric medicine clinic. However, some women may present for the first time with a complication during pregnancy such as the case reported by Lowik et al. 41 It is therefore important that obstetricians are aware of mitochondrial disease and its varied presentations to facilitate diagnosis of a first presentation in pregnancy.
Women with mitochondrial disease are likely to experience a variable clinical course before, during and after pregnancy. The results of this review suggest that they may well be at increased risk of complications during pregnancy and labour such as preterm delivery and preeclampsia. With the exception of Folgero et al., these studies did not report whether or not infants inherited mitochondrial disease. This will vary between mitochondrial diseases, but it would have been useful to know this, particularly when the genetic defect was unknown. More research is required to develop a better Magnesium toxicity understanding and ideally quantify all these risks in order to counsel women preconception and to plan and deliver care during pregnancy and delivery. This can only be achieved by studying large cohorts of patients with mitochondrial disease, exploring their obstetric history and prospectively collecting data on future pregnancies. Furthermore, women with mitochondrial disease may also not be suitable for routine obstetric care in the event of complications. For example, as magnesium may compete with calcium in mitochondria, interfering with oxidative phosphorylation 34 even at therapeutic levels, 35 women with mitochondrial disease appear to be at risk of toxicity if given magnesium sulphate for preeclampsia.
Mitochondrial medicine is a fast developing specialty 1 and, as mitochondrial disease already presents a number of challenges to obstetricians, it is likely that multidisciplinary care with colleagues from mitochondrial medicine, neurology and the other medical specialties is indicated. Links with fetal medicine are also important since offspring of affected women can be symptomatic early in life. 
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